Mubadala Participates in Private Placement in Evotec
Posted on 10/13/2020
Abu Dhabi-based Mubadala Investment Company is investing €200 million in Hamburg-based Evotec SE, a German pharmaceutical company. Mubadala will subscribe to 9.2 million Evotec shares, taking about a 5.6% stake in a private placement. Novo Holdings A/S will also invest €50 million to subscribe to 2.3 million shares in the company at the same price, taking its stake to about 11%.
Novo Holdings A/S is the Novo Nordisk Foundation’s wholly owned holding company for Novo Nordisk A/S and Novozymes A/S. Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation’s assets.
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate).
